These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24647522)

  • 1. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
    Dong X; Hao Y; Wei Y; Yin Q; Du J; Zhao X
    PLoS One; 2014; 9(3):e92320. PubMed ID: 24647522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
    Vilmar AC; Santoni-Rugiu E; Sorensen JB
    Ann Oncol; 2013 Feb; 24(2):309-314. PubMed ID: 23038758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
    Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
    PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
    Wang L; Meng L; Wang XW; Ma GY; Chen JH
    Tumour Biol; 2014 Mar; 35(3):1899-906. PubMed ID: 24155212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
    Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
    J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
    Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
    Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J
    Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
    Dong X; Zhao X; Hao Y; Wei Y; Yin Q; Du J
    Clin Lung Cancer; 2013 Nov; 14(6):680-7. PubMed ID: 23910066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
    Ma K; Li E; Guo Y; Wang X; Sun H; Shao G
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):505-10. PubMed ID: 25327655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z; Han B; Shen J; Gu A; Zhong H
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
    Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
    Br J Cancer; 2008 May; 98(10):1710-5. PubMed ID: 18414411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
    Liang JG; Jin ZY; Gao XD; Te MR; Ge LH; Wang CL
    Genet Mol Res; 2014 Jul; 13(3):5292-8. PubMed ID: 25078585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
    Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.